Hepatitis C News and Research

Latest Hepatitis C News and Research

Women face higher risk of graft loss after liver transplantation compared to men

Although women with chronic hepatitis C virus (HCV) infection are at lower risk for developing cirrhosis, researchers who compared outcomes for men and women after having liver transplantation found that women have a significantly increased risk of overall graft loss and graft loss from recurrent HCV than men.

30 Oct 2009

Dynavax Technologies announces first clinical data for HEPLISAV investigational hepatitis B vaccine

Dynavax Technologies Corporation today announced the first clinical data for HEPLISAVTM investigational hepatitis B vaccine in chronic kidney disease patients.

30 Oct 2009

Human Genome Sciences declares financial results for third quarter 2009; reports increased revenue growth

Human Genome Sciences, Inc. today announced financial results for the quarter ended September 30, 2009, and provided highlights of recent key developments.

30 Oct 2009

Roger Tung to receive 2009 Mass High Tech All Star award for his contributions to pharmaceutical industry

Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer, has been named a 2009 Mass High Tech All Star for his contributions to the pharmaceutical industry.

29 Oct 2009

Supportive data from a preclinical study of SCY-635 to be presented

Drug discovery company SCYNEXIS, Inc. today announced that supportive data from a preclinical study of the Company’s lead product candidate for hepatitis C (HCV), SCY-635, will be presented in a poster session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in Boston, MA, October 30-November 3, 2009.

29 Oct 2009

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the ‘Esau’ patent family (US Application Serial No. 10/909,125).

28 Oct 2009

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

28 Oct 2009

SciClone Pharmaceuticals reduces its U.S.-based workforce by 17% in research and development

SciClone Pharmaceuticals, Inc. today announced a corporate restructuring that will reduce its U.S.-based workforce by approximately 17%, primarily in research and development. This restructuring follows the discontinuation of SciClone's RP101 phase 2 clinical trial announced on October 2, 2009.

28 Oct 2009

Data from Phase II clinical trial of NKTR-118 presented

Data from a phase II study demonstrated that oral NKTR-118 improved lower gastrointestinal dysfunction by increasing the frequency of bowel movements in patients with opioid-induced constipation, while simultaneously preserving opioid-mediated analgesia.

28 Oct 2009

Biomagnetics Diagnostics completes negotiations to acquire IBOS technology

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company has completed business negotiations with one of the U.S. Government's top national security research institutions regarding the acquisition of rights to the Integrated Optical Biosensor System (IBOS) technology developed by the laboratory personnel. Biomagnetics Diagnostics plans to utilize this technology to enter the significantly underserved market for handheld biosensors capable of detecting a broad range of disease-causing viruses, bacteria and fungi.

28 Oct 2009

FDA issues clearance for Lumenis' PolyScope Flexible Endoscope

Lumenis Ltd., a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced that on September 30th, 2009 the FDA issued a 510K to Lumenis stating that the PolyScope Flexible Endoscope can now be sold in the United States.

From Lumenis Inc. 28 Oct 2009

Starting Grant from ERC to LMU junior researchers

Two junior researchers from Ludwig-Maximilians-Universit-t (LMU) in Munich shall each receive a Starting Grant from the European Research Council (ERC). Professor Jens Michaelis, Department of Chemistry and Biochemistry, and Privatdozent Dr. David V-hringer, Institute of Immunology, shall receive grants amounting to 1.4 and 1.7 million Euros over five years. With its Starting Grant, the ERC supports highly creative researchers in order to encourage pioneering frontier research.

27 Oct 2009

Phase 2 clinical study of PEG-Interferon lambda commenced

ZymoGenetics, Inc. today announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection (the “EMERGE” study).

27 Oct 2009

Vaccination rates need improvement; racial and ethnic disparities in vaccination coverage

More teenagers are being vaccinated against human papillomavirus (HPV), meningococcal meningitis and pertussis (whooping cough), though the rates are still too low, according to recently released government data and a panel of experts convened by the National Foundation for Infectious Diseases (NFID).

27 Oct 2009

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.

27 Oct 2009

Anti-viral drug development programs progress successfully, reports NanoViricides

NanoViricides, Inc. (the "Company"), reports that the Company is well financed and its game changing anti-viral drug development programs are progressing successfully. As such, Management knows of no reason for the recent decline in stock price and associated volatility.

26 Oct 2009

Wellcome Trust's 91M fund aims at developing new drugs related to the dengue fever virus

The Wellcome Trust spends over 600 million pounds each year to support its mission to foster and promote research with the aim to improving human and animal health. This funding supports basic research as well as technology transfer, the transfer of academic knowledge and technology to the corporate environment.

26 Oct 2009

New nucleic acid test to screen donated blood for HIV-1 Group M RNA approved

Health Canada has approved a new nucleic acid test from Roche Diagnostics to screen donated blood for HIV-1 Group M RNA, hepatitis C RNA and hepatitis B DNA in a single, automated assay.

From Roche Sequencing and Life Science 24 Oct 2009

Philippines calls for help to address disease outbreak in storms' aftermath

The WHO on Thursday said the Philippines is requesting "international help to fight a deadly outbreak of an infectious disease following two devastating tropical storms," Agence France-Presse reports. Parts of Manila, which are still flooded almost four weeks after Tropical Storm Ketsana hit, are experiencing an outbreak of the bacterial infection, leptospirosis (10/22).

24 Oct 2009

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

Medgenics is pleased to announce that it has signed a preclinical development and option agreement with a major international biopharmaceutical company that is a market leader in the field of hemophilia.

23 Oct 2009

Hepatitis C News and Research

Latest Hepatitis C News and Research

Women face higher risk of graft loss after liver transplantation compared to men

Dynavax Technologies announces first clinical data for HEPLISAV investigational hepatitis B vaccine

Human Genome Sciences declares financial results for third quarter 2009; reports increased revenue growth

Roger Tung to receive 2009 Mass High Tech All Star award for his contributions to pharmaceutical industry

Supportive data from a preclinical study of SCY-635 to be presented

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

SciClone Pharmaceuticals reduces its U.S.-based workforce by 17% in research and development

Data from Phase II clinical trial of NKTR-118 presented

Biomagnetics Diagnostics completes negotiations to acquire IBOS technology

FDA issues clearance for Lumenis' PolyScope Flexible Endoscope

Starting Grant from ERC to LMU junior researchers

Phase 2 clinical study of PEG-Interferon lambda commenced

Vaccination rates need improvement; racial and ethnic disparities in vaccination coverage

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

Anti-viral drug development programs progress successfully, reports NanoViricides

Wellcome Trust's 91M fund aims at developing new drugs related to the dengue fever virus

New nucleic acid test to screen donated blood for HIV-1 Group M RNA approved

Philippines calls for help to address disease outbreak in storms' aftermath

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis C News and Research

Latest Hepatitis C News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in